SEC-sourced researchBeta
VIR
Vir Biotechnology, Inc.
Company comparison ↗
Data passport
- CIK
- 0001706431
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Oct 1, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 86,180,000.0000 | Feb 23, 2026 |
| December 2024 | 74,205,000.0000 | Feb 23, 2026 |
| December 2025 | 68,556,000.0000 | Feb 23, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 68,556,000.0000 | -437,987,000.0000 | -391,781,000.0000 | 1,002,823,000.0000 | 237,547,000.0000 | Feb 23, 2026 |
| December 2024 | 74,205,000.0000 | -521,960,000.0000 | -446,352,000.0000 | 1,398,813,000.0000 | 248,428,000.0000 | Feb 23, 2026 |
| December 2023 | 86,180,000.0000 | -615,061,000.0000 | -778,785,000.0000 | — | — | Feb 23, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $68.56M | December 2025 | Feb 23, 2026 | 10-K |
| Previous period revenueRevenues | $74.21M | December 2024 | Feb 23, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$437.99M | December 2025 | Feb 23, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$391.78M | December 2025 | Feb 23, 2026 | 10-K |
| Total assetsAssets | $1B | December 2025 | Feb 23, 2026 | 10-K |
| Total liabilitiesLiabilities | $237.55M | December 2025 | Feb 23, 2026 | 10-K |